Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

November 27, 2015

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

Previous Article
Prehospital combination therapy disappoints in status epilepticus
Prehospital combination therapy disappoints in status epilepticus

Adding levetiracetam to prehospital treatment with clonazepam does not improve control of generalised convu...

Next Article
Freeze drying education program announced by SP Scientific
Freeze drying education program announced by SP Scientific

SP Scientific has announced their next series of educational events to be held during 2016 for scientists i...